Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent and debilitating complications of oncologic treatment. It affects between 30% and 68% of patients undergoing neurotoxic agents — especially taxanes (paclitaxel, docetaxel), platinum compounds (cisplatin, oxaliplatin), and vinca alkaloids (vincristine). Symptoms include numbness, tingling, burning pain, muscle weakness, and loss of sensation in the hands and feet — compromising quality of life, functional capacity, and frequently forcing interruption or reduction of the chemotherapy regimen. Conventional medicine has no effective preventive treatment for CIPN, and analgesic options (duloxetine, gabapentin) have modest efficacy. A network meta-analysis published in BMC Complementary Medicine and Therapeutics in August 2024 offers the most comprehensive overview ever compiled on the use of acupuncture for CIPN: 33 randomized clinical trials and 2,027 patients, with simultaneous comparison of multiple acupuncture modalities.
The study was conducted by Mei-Ling Yeh and colleagues, with systematic search across nine databases through May 2023. The network meta-analysis methodology — methodologically superior to conventional meta-analysis for comparing multiple interventions simultaneously — allows ranking of modalities by efficacy even when individual trials did not test them directly against each other. The study evaluated the following interventions: conventional acupuncture, electroacupuncture (EA, acupuncture with electrical stimulation), acupuncture with moxibustion, reflexology, and combinations of these modalities, always compared with usual care, conventional medication, or dietary supplementation.
NETWORK META-ANALYSIS OF ACUPUNCTURE FOR CIPN (BMC COMPLEMENTARY MEDICINE AND THERAPEUTICS, AUGUST 2024)
What is the Network Meta-Analysis and Why is it Superior?
Conventional meta-analysis compares only two groups — for example, acupuncture vs. control. The network meta-analysis (NMA) integrates direct and indirect comparisons simultaneously, allowing classification of multiple interventions in a hierarchy of efficacy even when individual trials did not test them against each other. The result is expressed in SUCRA (Surface Under the Cumulative Ranking Curve) — the higher the SUCRA, the higher the probability of being the best intervention for that outcome. This method is considered the most advanced standard for evidence synthesis when there are multiple therapeutic alternatives to compare.
The central finding of the NMA is that there is no single “best” acupuncture modality for CIPN — the answer depends on the prioritized outcome. For general CIPN symptoms (composite score of numbness, tingling, weakness), electroacupuncture led the ranking. For specific neuropathic pain — the symptom most impactful on quality of life — conventional acupuncture was superior. For overall quality of life, the combination of acupuncture with moxibustion reached first rank. This differentiation is clinically relevant: the choice of modality should be guided by the patient’s predominant symptom profile.
Results by Outcome: Symptoms, Pain, and Quality of Life
The network meta-analysis demonstrated that all evaluated acupuncture modalities were superior to usual care, conventional medication, and dietary supplementation for at least one outcome. For general CIPN symptoms — assessed by composite scales such as the Total Neuropathy Score (TNS) and the FACT-GOG/NTx score — electroacupuncture led the SUCRA ranking, followed by conventional acupuncture. The addition of electrical stimulation amplifies pain modulation mechanisms (activation of segmental and suprasegmental inhibitory pathways) and may explain EA’s advantage over conventional acupuncture in the composite outcome.
For isolated neuropathic pain — the symptom most frequently reported as most limiting by patients with CIPN — conventional acupuncture (without electrical stimulation) reached first rank. This counterintuitive finding may reflect the fact that the intensity of stimulation in electroacupuncture, in patients with compromised peripheral sensitivity, is not optimized uniformly — and that the fine adjustment by the medical acupuncturist through manual technique (search for de qi, variation in depth and angle of insertion) may be more precise for specific pain. The result on quality of life — with acupuncture + moxibustion in first rank — suggests that the addition of moxibustion contributes additional therapeutic components: local heat (improves circulation in the limbs), antioxidant effect of compounds released by Artemisia combustion, and neuroendocrine modulation of heat at the acupoints.
Frequently Asked Questions
Reversibility of CIPN depends on the chemotherapy agent, accumulated dose, time of exposure, and individual factors (genetic, metabolic, nutritional status). In many cases, especially with taxanes, neuropathy improves spontaneously months after the end of chemotherapy. With platinums — particularly oxaliplatin — CIPN may be persistent or even progressive after treatment. Acupuncture does not directly “regenerate” the damaged axon, but may modulate neuroinflammation (reducing factors that perpetuate damage), stimulate neurotrophins (NGF, BDNF) that support axonal regeneration, and improve peripheral circulation in affected limbs. Clinical improvement observed in trials reflects a combination of neuroprotective and analgesic effects — not exclusively structural regeneration.
Yes, when performed by a medical acupuncturist with experience in oncology and adapted to the patient’s hematologic state. Main precautions: (1) severe thrombocytopenia (platelets <50,000/mm³) — reduce number of needles and depth of insertion, avoid áreas with compromised circulation; (2) neutropenia (neutrophils <500/mm³) — greater care with asepsis; (3) lymphedema in post-surgical limbs — avoid needling in the affected limb; (4) severe peripheral neuropathy — greater risk of inadvertent tissue trauma due to loss of protective sensation. Direct communication between the medical acupuncturist and the responsible oncologist is fundamental for protocol adjustment to the clinical state of each chemotherapy cycle.
The agents with greatest peripheral neurotoxicity are: platinum compounds (oxaliplatin > cisplatin > carboplatin) — especially for colorectal, lung, and ovarian cancer; taxanes (paclitaxel > docetaxel) — for breast, ovarian, and lung cancer; vinca alkaloids (vincristine > vinblastine) — for lymphomas and leukemias; bortezomib (proteasome inhibitor) — for multiple myeloma; thalidomide/lenalidomide — for myeloma. Oxaliplatin causes two distinct patterns: acute CIPN (cold pain, immediate spasms after infusion) and chronic CIPN (cumulative sensory neuropathy). Acupuncture has specific data for these agents — the medical acupuncturist should know the patient’s chemotherapy regimen to adjust the protocol appropriately.
Fonte Original
BMC Complementary Medicine and Therapeutics(em inglês)Founded in 1989 by physicians trained at the University of São Paulo (USP) and specialized in China, CEIMEC is a Brazilian national reference in the teaching and practice of medical acupuncture. With more than 3,000 physicians trained over 35 years, it collaborates with HC-FMUSP and is recognized by the Brazilian Medical College of Acupuncture (CMBA/AMB).